

1 **Title:**

2 Rapid and modular workflows for same-day sequencing-based detection of bloodstream
3 infections and antimicrobial resistance determinants

4 **Authors:**

5 Mohammad Saiful Islam Sajib¹, Katarina Oravcova¹, Kirstyn Brunker^{1,2}, Paul Everest¹, Manuel
6 Fuentes¹, Catherine Wilson³, Michael E. Murphy^{3,4}, Taya Forde¹

7 **Affiliations:**

8 ¹School of Biodiversity, One Health & Veterinary Medicine, University of Glasgow, Glasgow,
9 United Kingdom

10 ²MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom

11 ³Department of Microbiology, NHS Greater Glasgow and Clyde, Glasgow Royal Infirmary, New
12 Lister Building, Alexandra Parade, Glasgow, UK

13 ⁴School of Medicine, Dentistry & Nursing, College of Medical, Veterinary & Life Sciences,
14 Wolfson Medical School Building, University of Glasgow, Glasgow, UK

15 **Keywords:**

16 rapid diagnosis, selective host depletion, chemical host depletion, metagenomic next
17 generation sequencing, Oxford Nanopore technologies, selective sequencing, adaptive
18 sampling, bloodstream infection, antimicrobial resistance

19

20

21

22

23

24

25

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

26 **Abstract:**

27 **Background:** Bloodstream infections (BSI) are a major global health concern, and existing
28 diagnostic methods are too slow to guide targeted antibiotic therapy for critically ill patients,
29 risking poor clinical outcomes. Rapid metagenomic-sequencing (mNGS) can facilitate swift
30 pathogen and antimicrobial resistance (AMR) detection, but identification is challenged by
31 significant host versus bacterial DNA in blood. To accelerate microbiological diagnosis, we
32 developed M-15, a rapid and modular mNGS-based host DNA depletion workflow, validated
33 with suspected BSI blood-culture samples and rapid culture-enriched spiked blood.

34 **Methods:** To assess chemical host DNA depletion (CHDD) efficiency, M-15 was benchmarked
35 with five commercial/published protocols. Later, M-15 was combined with rapid mNGS
36 with/without adaptive sampling (AS) and tested on clinical blood-culture samples (n=33) from
37 suspected BSI cases identified on BACT/ALERT VIRTUO (30 flagged positive, three remained
38 negative). To determine whether it is possible to utilise M-15 mNGS prior to blood-culture
39 flagging positive, a rapid enrichment method was tested starting with 1-10 colony forming
40 units of the top 15 bacterial species causing BSI spiked into BACTEC medium enriched with 10
41 mL sheep blood.

42 **Results:** All six chemical depletion protocols reduced host DNA by 2.5×10^0 to 4.1×10^6 -fold,
43 with the in-house M-15 protocol performing best, while adaptive sampling depleted host >5-
44 fold. With BACT/ALERT specimens, M-15 mNGS accurately identified 3/3 negative, 28/28
45 mono-bacterial, and 2/4 multi-bacterial species. With rapid culture-enrichment and M-15
46 mNGS, <18% DNA was classified as host and all bacterial species tested (n=10) were correctly
47 identified. M-15 mNGS accurately predicted phenotypic AMR/susceptibility for 90.3%
48 (232/257) of drug/bacteria combinations from BACT/ALERT positive samples.

49 **Conclusions:** This study demonstrates that M-15 mNGS can facilitate species and AMR gene
50 detection within 5-7 hours of BACT/ALERT positivity. Including 8-hour culture enrichment,
51 microbiological and AMR confirmation is possible within 13-15 hours of sample collection.
52 Thus, the M-15 mNGS workflow has the potential to improve patient outcomes in BSI.

54 Background

55 Bloodstream infection (BSI) is one of the leading causes of death worldwide, with 2.9 million
56 cases each year [1]. Rapid identification of the causative bacterial pathogens and their
57 antimicrobial resistance (AMR) profiles is crucial for guiding more effective treatment and
58 better patient outcomes, especially for critically ill patients such as those who develop sepsis
59 [2]. Blood culture, the gold standard diagnostic method, often takes 48-72 hours, which is too
60 slow to guide targeted antibiotic therapy. This necessitates the prescription of empirical
61 antibiotics, which may fail to cover the resistance profile of the causative pathogen and risk
62 poor clinical outcomes [3]. Also, the use of broad-spectrum antibiotics to limit disease
63 progression may disrupt beneficial gut microbiota and contribute to the development of
64 multidrug-resistant bacteria often associated with healthcare infections, further limiting the
65 reserve of critically important antimicrobial agents [4]. Thus, there is an urgent need for rapid
66 diagnostic tools to better inform antibiotic regimens at the early stages of BSI.

67 Certain applications of metagenomic next-generation sequencing (mNGS) could be used to
68 rapidly identify bacterial species and AMR determinants, and therefore have the potential to
69 accelerate BSI diagnosis [5]. However, the proportion of host DNA in blood compared to that
70 of bacteria makes it challenging to directly sequence and generate adequate reads from the
71 pathogen to accurately identify species and AMR in a cost-effective manner and within a
72 clinically relevant timeframe. To address this issue, we developed a rapid mNGS-based
73 chemical host DNA depletion (CHDD) protocol, named M-15, and compared its performance
74 with two commercial kits (C1-2) and three published methods (P1-3) [6-8]. Next, M-15 mNGS
75 was validated with and without nanopore adaptive sampling using both culture (BACT/ALERT
76 an automated blood culture system) positive and negative enriched blood samples collected
77 from patients with suspected BSI. Finally, M-15 was combined and tested with a rapid (8-
78 hour) culture (BACT/ALERT) enrichment step to reduce turnaround time and enable same-day
79 microbiological diagnosis of bloodstream infections.

80 Methods

81 Bacterial strains and host matrix

82 Defibrinated sheep blood (E&O Laboratories, UK) and EDTA-treated whole blood from healthy
83 human volunteers were used as model host environment matrix. The list of clinical and/or

84 American Type Culture Collection (ATCC) strains tested/used in this study can be found in **Tab.**
85 **1, S1, S2 and S3.**

86 **Primers, probes, and amplification parameters**

87 To assess the depletion efficiency of the protocols, universal 16S rRNA, 18S rRNA and
88 bacterial species-specific primers and probes were utilised [9-12]. The total volume of
89 individual qPCR reactions was 20 µL, with 2x Rotor-Gene Multiplex PCR master mix (Qiagen,
90 Hilden, Germany) and 2 µL DNA template. qPCR reactions were performed on a Rotor-Gene Q
91 real-time cycler for up to 40 cycles (Qiagen, Hilden, Germany). The primer/probe sequences,
92 concentrations and PCR cycling parameters are provided in **Tab. S4.**


93 **Benchmarking host depletion kits and protocols**

94 A chemical host DNA depletion protocol, named M-15, was developed in this study (**Fig. 1,**
95 **Supplement Protocol: M-15 mNGS**) and benchmarked alongside two commercial [Zymo-
96 HostZERO (named C1; Zymo Research, CA, USA), MoLYsis-Complete5 (C2; Molzym GmbH &
97 Co, Bremen, Germany)] and three published host depletion protocols P1 [6], P2 [8], and P3
98 [7].

99 To determine host depletion efficiency and analytical sensitivity of the workflows, serially
100 diluted (10⁰ to 10⁵ CFU/mL) exponential growth phase cells of *Escherichia coli* (ATCC 25922),
101 *Staphylococcus aureus* (ATCC 25923), and *Pseudomonas aeruginosa* (ATCC 27853) strains
102 were spiked in 400 µL sterile whole blood (human and sheep) and processed to deplete host
103 cells/DNA with all the six protocols. Following host depletion with P1, P2, P3 and M-15, DNA
104 extraction was performed using QIAamp UCP Pathogen Mini Kit (Qiagen, Hilden, Germany)
105 with the recommended homogenisation step by bead beating (Pathogen Lysis Tubes L,
106 Qiagen, Hilden, Germany). For protocols C1 and C2, DNA extraction was performed using the
107 reagents supplied with the kits. Total DNA was extracted from the same spiked blood samples
108 without host depletion similarly as unenriched (non-CHDD) controls. Extracted DNA was
109 tested using qPCR with the 16S rRNA, 18S rRNA, and species-specific primers/probes
110 described above.

111 In addition, a subset of the simulated M-15 CHDD samples, containing 10⁴ to 10¹ CFU/mL
112 blood was extracted, amplified and barcoded for sequencing using ONT Rapid PCR barcoding

113 kit (SQK-RPB004; Oxford Nanopore technologies, Oxford, UK) and sequenced on MinION
 114 R9.4.1 flow cells. Live GPU basecalling was performed in high accuracy mode
 115 (dna_r9.4.1_450bps_hac) and passed Fastq reads were analysed using Chan Zuckerberg
 116 infectious diseases (CZ ID) (v0.7; <https://czid.org/>) Nanopore workflow (last accessed:
 117 07/08/2024) [13].



118

119 **Fig. 1: Schematic diagram depicting major steps involved in M-15 CHDD and mNGS workflow.** Both
 120 BACTEC flagged positive and rapid enriched (8-hour), blood culture samples can be used as input. M-
 121 15 CHDD is the first step where host DNA is selectively depleted with saponin and DNase I treatment.
 122 Host depleted material is then subjected to alkaline lysis and whole genome amplification with REPLI-g
 123 single cell kit. Amplified product is then debranched using T7 Endonuclease I and sequencing is
 124 performed with rapid barcoding (mid-low yield) or native barcoding (high-yield) kit.

125 Determining the contribution of host depletion on bacterial cell loss/viability

126 Bacterial cell loss and/or viability following host depletion was determined using *E. coli*, *S.*
 127 *aureus*, and *P. aeruginosa* ATCC strains. Approximately 30 and 3 CFU of the exponential phase
 128 cells were spiked in 400 μ L sterile whole blood, and the samples were processed to deplete
 129 host DNA with three top performing protocols C1, C2, P1, and M-15. Host depleted samples
 130 were resuspended in PBS and plated on nutrient and blood agar media to estimate bacterial
 131 concentrations using the method described by Miles & Misra [14]. The same samples were

132 plated directly without host depletion as controls. All the inoculated plates were incubated
133 overnight at 37°C, and the number of visible colonies was recorded the next day.

134 **Rapid M-15 mNGS workflow tested on culture enriched specimens**

135 To determine the efficiency of M-15 mNGS protocol on culture enriched samples, six culture
136 enriched suspected BSI samples were tested initially. Three samples flagged positive on
137 BACT/ALERT (bioMérieux, Marcy-l'Étoile, France) and the remaining three were reported to
138 be culture negative. The same samples were processed directly without M-15 as no depletion
139 controls. To minimise hands on time, rapid alkaline cell lysis was performed using 4 µL direct
140 or host depleted samples resuspended in 1 mL PBS using REPLI-g single cell kit (Qiagen,
141 Hilden, Germany). Multiple displacement amplification (MDA) was performed with the same
142 kit for 60 minutes according to the manufacturer's recommendation. Amplified MDA
143 products were then debranched for 10 minutes at 37° C using T7 endonuclease (New England
144 Biolabs, MA, United States) and subjected to 0.5x AMPure bead cleanup. Library was
145 prepared using ONT Rapid barcoding kit (SQK-RBK004) with 400 ng amplified debranched
146 DNA product/sample as an input (**Supplement Protocol: M-15 mNGS + low-medium yield
147 protocol**). The overall sample processing time of this pilot version of the workflow is
148 approximately 4 hours (processing 6-10 samples), including 80 minutes for host depletion, 20
149 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-g Single
150 Cell Kit, and 90 minutes for debranching, cleanup, library preparation and flow cell loading.

151 To assess the efficiency of adaptive sampling (AS) with or without CHDD with M-15, rapid
152 adapter ligated pooled libraries (six CHDD and six no CHDD) were loaded on a MinION R9.4.1
153 flow cell and the total number of channels (N= 512) available for sequencing were divided
154 into two parts from the advanced option menu on the MinKNOW graphical user interface.
155 Channels 1 to 256 were chosen for human DNA depletion using T2T-CHM13v2.0 as reference
156 [15] and channels 257-512 for no-adaptive sampling control.

157 **High yield M-15 mNGS workflow validated with culture-positive suspected BSI specimens**

158 An additional 27 blood culture positive samples were tested using the optimised workflow for
159 improved sequencing yield. Chemical host depletion, DNA extraction, MDA (60 minutes) and
160 debranching were performed similarly to the pilot protocol. Only this time, library preparation
161 was performed using Ligation Sequencing Kit (SQK-LSK109) with native barcodes (EXP-

162 NBD104) with 400 ng amplified debranched DNA product/sample as an input (**Supplement**
163 **Protocol: M-15 mNGS + high yield protocol**). The overall sample processing time of this
164 optimised workflow takes less than 6 hours (with 6-10 samples) including 80 minutes of
165 CHDD, 20 minutes for DNA extraction (alkaline lysis method), 60 minutes of WGA using REPLI-
166 g Single Cell Kit, and about 180 minutes for debranching, library preparation and loading.

167 To identify bacterial species, CZ ID pipeline was utilised as mentioned above with a 20%
168 abundance cutoff (200,000 Base Per Million; BPM for CZ ID). Host-filtered contigs remaining
169 after the 20% abundance cutoff were analysed to identify AMR determinants with ResFinder
170 4.5.0 [16] using the default options. In addition, host filtered fastq reads remaining after 20%
171 abundance cutoff were mapped against bacterial reference sequences using minimap2[17] to
172 estimate the breadth of coverage and sequencing depth. To determine the minimum
173 sequencing yield required to identify bacterial species and AMR determinants, 100 Mbp, 50
174 Mbp, 40 Mbp, 30 Mbp, 20 Mbp, and 10 Mbp raw fastq reads were randomly subsampled
175 using rasusa [18] and processed similarly with CZ ID and ResFinder.

176 **Rapid culture enrichment to accelerate microbiological diagnosis**

177 A shorter culture enrichment method was tested with 16 ATCC/clinical isolates representing
178 eight Gram negative and seven Gram positive bacterial species. Approximately 1-10 CFU of
179 actively growing (log phase) bacterial cells were spiked in BD BACTEC™ Standard Blood
180 Culture media (Becton, Dickinson and Company, NJ, USA) supplemented with 10 mL sterile
181 whole blood (sheep), and then subjected to incubation. Culture bottles were taken out at 2-
182 hour intervals over a span of 10 hours and subsequently plated on nutrient and blood agar
183 media using the Miles & Misra method.[14] All the plates were incubated at 37°C overnight
184 and the number of visible colonies was recorded the next day. One mL culture-enriched
185 samples were preserved at -80°C during each sampling session to be tested later. Finally, a
186 subset (10/16) of the 8-hour culture-enriched samples (5 Gram-positive and 5 Gram-negative
187 species) were chosen and processed with the high yield M-15 mNGS protocol (**Supplement**
188 **Protocol: M-15 mNGS + high yield protocol**). Species, host: pathogen ratio, antimicrobial
189 resistance genes and minimum DNA yield per sample for identification were determined
190 using the same pipelines and cutoffs mentioned above.

191

192 Conventional tests for detecting species, AMR, and predicting AMR with sequencing

193 In the routine diagnostic microbiology laboratory, 5-10 mL EDTA treated blood samples
194 collected from suspected individuals were incubated in the BACT/ALERT system for up to 5
195 days. Samples that flagged positive were taken out and inoculated onto appropriate agars,
196 and organisms grown identified using MALDI-TOF mass spectrometry (Bruker Corporation,
197 MA, USA). Phenotypic antimicrobial sensitivity was determined using disc diffusion as
198 described by European Committee on Antimicrobial Susceptibility Testing (EUCAST) guideline
199 [19] or automated systems, e.g. Vitek2 (bioMérieux, Marcy-l'Étoile, France).

200 To compare routine phenotypic sensitivity and genotypic antimicrobial susceptibility results,
201 AST results for the BACT/ALERT positive BSI samples were compared to ResFinder 4.5.0
202 phenotype table results. Because ResFinder provides AMR predictions for 92 antimicrobial
203 agents from 21 antibiotic classes, but only predicts resistance or susceptibility (not
204 Intermediate results), only the phenotypic results common between the two (culture and
205 sequencing) and classified as resistant or susceptible were compared. For rapid culture
206 enriched spiked blood samples, for which AST results were not available, WGS (where
207 available) and M-15 mNGS data of the ten ATCC/clinical isolates were compared similarly
208 using ResFinder 4.5.0 phenotype table. Categorical agreement, major error and very major
209 error were calculated using the following formula [20]:

$$210 \quad \text{Categorical agreement} = \frac{\text{TR} + \text{TS}}{\text{TR} + \text{TS} + \text{FR} + \text{FS}}$$

211

$$212 \quad \text{Major error} = \frac{\text{FR}}{\text{FR} + \text{TS}}$$

213

$$214 \quad \text{Very major error} = \frac{\text{FS}}{\text{FS} + \text{TR}}$$

215 Where: TR = True resistant, TS = True susceptible, FR = False resistant, FS = False susceptible,
216 and where phenotypic AST is taken as the gold standard.

217

218

219 Statistical analysis

220 R studio 2023.12.1 with R base version 4.3.3 were used in combination with readxl, dplyr,
221 reshape2, ggplot2, and gridExtra packages for performing data cleanup, formatting, analysis
222 and generating graphs.

223 Results

224 Chemical depletion protocols remove unwanted host with high efficiency

225 Protocols M-15 and P1 removed 4.1×10^6 (Quantification cycle ΔCt -20.52) and 5.5×10^5 fold (ΔCt -17.45)
226 host DNA, respectively, from the whole blood samples spiked with *Escherichia coli*, *Staphylococcus*
227 *aureus*, or *Pseudomonas aeruginosa* ATCC strains, with depletion efficiency over 99.99%. Commercial
228 kit C1 removed 99.82% (5.87×10^2 fold) host, and C2, 97.93% (4.84×10^1 fold). Approximately 81.09%
229 and 59.19% host were removed with the protocols P2 and P3, respectively (**Tab. 1**). Between 5.58%
230 (P3) and 51.63% (M-15) bacterial DNA were removed during host depletion with the six
231 kits/protocols. Protocols with higher depletion efficiencies also exhibited increased bacterial
232 DNA loss (**Tab. 1**).

233 Protocol C2 exhibited a strong negative bias towards *P. aeruginosa*, as >99% (ΔCt -10.27) loss
234 was observed, possibly due to the detrimental effect of buffer CM (a selective host cell lysis
235 buffer provided in the kit) on this bacterial species during the host lysis steps. In a recent
236 study, where blood culture positive samples were processed with protocol C2 to deplete host
237 and enable rapid sequencing-based species and AMR identification [20] sequencing results
238 also indicated suboptimal accuracy of C2 mNGS for *P. aeruginosa* compared to other bacterial
239 species, possibly indicating similar lysis bias [20].

240 **Tab. 1:** Host depletion efficiency and bacterial DNA loss observed with in-house chemical host DNA
241 depletion method, M-15, compared with two commercial kits (C1-2) and 3 published protocols (P1-3).

Organism	Methods/Kits	Ct (SD)		Δ Ct	Fold Reduction	DNA Removal (%)
		No chemical depletion	Chemical depletion			
Host depletion efficiency						
<i>Ovis aries</i>	M-15 (this study)	16.24 (0.79)	36.76 (1.82)	-20.5	4.1×10^6	99.99998%
<i>Ovis aries</i>	P1 [6]	16.24 (0.79)	33.69 (0.99)	-17.5	5.5×10^5	99.99982%
<i>Ovis aries</i>	Zymo HostZero (C1)	20.30 (0.58)	29.74 (2.10)	-9.43	5.9×10^2	99.82966%
<i>Ovis aries</i>	Molysis Complete 5 (C2)	20.51 (0.64)	25.73 (1.08)	-5.2	4.8×10^1	97.93324%
<i>Ovis aries</i>	P2 [7]	18.97 (0.49)	21.15 (0.53)	-2.2	5.3×10^0	81.09315%
<i>Ovis aries</i>	P3 [8]	18.97 (0.49)	20.15 (0.51)	-1.2	2.5×10^0	59.19500%
Bacterial loss						
<i>E. coli</i>	M-15 (this study)	23.69 (1.04)	23.91 (0.47)	-0.22	1.3×10^0	23.87932%
<i>E. coli</i>	P1 [6]	23.94 (0.43)	22.41 (0.22)	1.5	0.35	0.00%
<i>E. coli</i>	Zymo HostZero (C1)	24.57 (0.34)	25.34 (0.65)	-0.8	1.6×10^0	37.93000%
<i>E. coli</i>	Molysis Complete 5 (C2)	23.73 (0.67)	23.27 (0.55)	0.5	0.74	0.00%
<i>E. coli</i>	P2 [7]	22.18 (0.28)	22.84 (0.73)	-0.7	1.5×10^0	31.14783%
<i>E. coli</i>	P3 [8]	22.18 (0.28)	21.39 (0.24)	0.8	0.58	0.00%
<i>P. aeruginosa</i>	M-15 (this study)	23.09 (0.46)	24.26 (0.66)	-1.2	2.1×10^0	53.08692%
<i>P. aeruginosa</i>	P1 [6]	21.84 (0.32)	23.53 (0.27)	-1.7	3.3×10^0	69.37233%
<i>P. aeruginosa</i>	Zymo HostZero (C1)	25.98 (0.23)	26.70 (0.17)	-0.7	1.7×10^0	39.94829%
<i>P. aeruginosa</i>	Molysis Complete 5 (C2)	25.03 (0.38)	35.31 (1.79)	-10.3	6.8×10^2	99.85400%
<i>P. aeruginosa</i>	P2 [7]	23.62 (0.46)	24.09 (0.23)	-0.5	1.4×10^0	30.04768%
<i>P. aeruginosa</i>	P3 [8]	23.56 (0.44)	23.43 (0.44)	0.1	0.92	0.00%
<i>S. aureus</i>	M-15 (this study)	20.59 (1.15)	22.49 (0.32)	-1.9	4.5×10^0	77.91082%
<i>S. aureus</i>	P1 [6]	21.94 (1.06)	22.74 (0.40)	-0.8	2.0×10^0	50.21738%
<i>S. aureus</i>	Zymo HostZero (C1)	26.76 (0.62)	26.07 (0.27)	0.7	0.66	0.00%
<i>S. aureus</i>	Molysis Complete 5 (C2)	22.78 (0.31)	23.33 (0.61)	-0.6	1.4×10^0	28.46943%
<i>S. aureus</i>	P2 [7]	22.78 (0.31)	23.46 (0.23)	-0.7	1.6×10^0	38.07282%
<i>S. aureus</i>	P3 [8]	22.78 (0.31)	23.04 (0.26)	-0.3	1.2×10^0	16.75203%

242 SD: Standard deviation, Ct: Cycle threshold, Δ Ct: Difference in quantification cycle

243 **CHDD protocols perform poorly with samples containing low bacterial concentrations**

244 Although the host depletion efficiency of some of the protocols, including M-15 was


245 encouraging, we observed some bacterial loss. Therefore, we aimed to evaluate their

246 applicability on blood samples with low bacterial concentrations (1 to 100 CFU/mL), as
247 typically seen in BSI cases [21]. For this, we selected the top performing protocols, M-15, P1,
248 C1 and C2, which exhibited the highest host depletion efficiency. For all three ATCC strains
249 tested (*E. coli*, *S. aureus*, *P. aeruginosa*), qPCR analytical sensitivity of protocols M-15, P1 and
250 C1 was 10² CFU/mL. With protocol C2, qPCR was able to detect up to 10¹ CFU/mL *E. coli* and
251 *S. aureus*; however, like before, Ct values from *P. aeruginosa* spiked CHDD samples were
252 consistently very high (Ct >30) across all five *P. aeruginosa* concentrations (10⁰ to 10⁴ CFU/mL)
253 spiked in whole blood (**Fig. 2A**).

254 To understand which part (chemical wash or DNA extraction) of the CHDD protocols is
255 contributing to reduced recovery of bacterial DNA, we processed low abundant spiked samples
256 (<30 and <3 CFU/mL) with M-15, P1, C1 and C2 protocols and confirmed viability/recovery with
257 culture. Viable plate counts following CHDD showed protocols C1 retained 92%, M-15 76% and
258 P1 62% of bacteria of the low initial counts of <30 cells spiked in blood (**Fig. 2B**). With even
259 lower concentration (<3 cells), the overall bacterial recovery rate with protocols C1, M-15, and
260 P1 were 72%, 43% and 13% respectively compared to the no CHDD controls (**Fig. 2B**). No viable
261 bacteria were recovered using protocol C2 for any of the bacterial species or samples tested;
262 again, possibly indicating buffer CM's effect on their growth or viability, although *P. aeruginosa*
263 was the only species (specifically ATCC 27853) tested in this study that displayed suboptimal
264 performance with downstream molecular assays (**Fig. 2B**).

265 In order to estimate the proportions of expected bacterial DNA (i.e., bacterial species spiked
266 initially) versus host and others (unclassified and other species), a subset of simulated M-15
267 CHDD samples (highest host depletion efficiency; 4.1×10⁶ fold), having 10⁴ to 10¹ *E. coli* CFU/mL
268 were sequenced. While the host: bacteria DNA ratio might differ between bacterial species
269 due to the difference in their genome size, this would facilitate estimating the lowest bacterial
270 concentration (CFU/mL) that would most likely provide consistent results with downstream
271 molecular applications, especially sequencing. The proportion of expected bacterial (*E. coli* that
272 were initially spiked) DNA sequence yield (mega base pairs; Mbp) in M-15 CHDD samples were
273 53.4% and 9.7% of total DNA for samples containing 10⁴ and 10³ CFU/mL bacteria respectively.
274 For low abundant samples, bacteria represented only 1.1% (10² CFU/mL) and 0.2% (10¹
275 CFU/mL) of total DNA yield following >99.99% host removal with M-15 (**Fig. 2C**). Proportion of
276 DNA sequence yield from expected bacterial species compared to the host remained

277 unchanged throughout the sequencing run regardless of bacterial concentration spiked or DNA
 278 ratio (Fig. 2C). The suboptimal host: pathogen ratio in low abundant blood samples meant that
 279 sequencing-based assays may not yet provide satisfactory results even with CHDD, unless an
 280 additional enrichment/depletion step is included pre/post DNA extraction to further improve
 281 bacterial proportions, and a more robust and sensitive DNA extraction method is benchmarked
 282 and validated.



283

284 **Fig. 2: Overall performance of M-15 versus published/commercial protocols (A)** qPCR Ct values
 285 (median and standard deviation) of different concentrations (10^4 to 10^0 CFU/mL – see legend) of
 286 three ATCC strains (*Escherichia coli*, *Pseudomonas aeruginosa*, and *Staphylococcus aureus*) spiked in
 287 whole blood and processed with top chemical host DNA depletion (CHDD) kits/protocols (P1, M-15,
 288 C1, and, C2) performing the best in terms of host DNA depletion. **(B)** Number of viable cells recovered
 289 from blood samples spiked with <30 and <3 CFU of the three ATCC strains following CHDD with P1, M-
 290 15, C1, and, C2, compared to the no CHDD/PBS control. **(C)** Proportion of expected bacteria initially
 291 spiked in blood for M-15 CHDD, compared to host (sheep) DNA, other bacterial species (different from
 292 the three species spiked), and unclassified reads, over 16 hours of MinION sequencing. The four facets
 293 are showing simulated/spiked bacterial concentration ranging from 10^4 to 10^1 CFU/mL of sheep blood.

294 M-15 mNGS and adaptive sampling significantly improve bacterial proportions


295 Due to suboptimal performance of M-15 mNGS observed with low bacterial concentrations
 296 directly in blood samples, three BACT/ALERT positive (BCP01-BCP03) and three negative

297 (BCN01-BCN03) culture enriched samples from suspected BSI cases were initially tested with
298 a rapid version of M-15 CHDD protocol (**Fig. 1**).

299 Length of the sequencing reads varied significantly among organisms, with expected bacterial
300 species (species that were identified with culture-based methods) having the highest median
301 read length (1,957 bp); this was 8.15x longer than the unclassified reads (240 bp), 3.52x
302 longer than human reads (552 bp) and 1.7x longer than other bacterial reads (mixed bacterial
303 species not expected from the sample; 1,145 bp) (**Fig. 3A**). The read length difference
304 between host and bacteria could be the result of CHDD, as host DNA was digested with
305 DNase I following selective lysis.

306 Overall yield in the adaptive sampling (AS) channels (1-256) was 1.86x lower (550.33 Mbp AS
307 vs 1023.72 Mbp no-AS) than no-AS (channels 257-512), although the total number of reads
308 for AS and no-AS samples was almost the same, with 345,085 and 334,054 reads,
309 respectively. Median read length for AS channels was 3.2x shorter than the no-AS, and host
310 constituted >90% of the reads that were smaller than 1kb in AS channels (**Fig. 3B**). This
311 illustrates that AS influenced the length of sequenced fragments as a result of its limited
312 ability to deplete shorter host reads (≤ 1 Kbp), which were highly abundant in the directly
313 extracted no-CHDD samples.

314 Samples processed with M-15 CHDD had 1.14×10^3 times less human DNA compared to the
315 no CHDD controls (based on sequencing yield in Mbp; **Fig. 3D**). Samples sequenced using AS
316 had 5.52-fold less human DNA compared to the controls; however, no bacterial enrichment
317 was observed (**Fig. 3C, 3D**). This highlights the importance of host depletion even in positively
318 flagged culture-enriched specimens, as it may lead to lower sequencing cost per sample, and
319 more importantly, reduce the sequencing time required to reach a desired yield for
320 determining the bacterial species responsible for the BSI.



321

322 **Fig. 3: Host depletion efficiency of M-15 mNGS and adaptive sampling (AS), versus no chemical**
 323 **host DNA depletion (CHDD) and no AS, tested with patient samples (A)** Violin plot showing size
 324 size distribution of sequencing reads aligned to expected bacterial species, host (human), other bacterial
 325 species, and reads for which there were no matches within the blast Nr/Nt database. **(B)** Histogram
 326 highlighting the number of raw sequencing reads from expected bacteria, host, others (other
 327 bacteria or unclassified). Coloured facets subdividing the raw reads further to distinguish read length
 328 variation by AS, no AS and CHDD and no CHDD. **(C)** Overall sequencing yield of CHDD and no-CHDD
 329 samples sequenced, comparing AS and no-AS. Stacked coloured bars highlight the proportion of DNA
 330 aligned to host, bacteria and others/unclassified species (see legend). Blood culture positive (BCP)
 331 samples are shown in red text, while blood culture negative (BCN) samples are shown in black. **(D)**
 332 Depletion efficiency (fold difference, FD) in DNA yield (Mbp) of sequences from host with CHDD and
 333 AS compared to no-CHDD and no-AS.

334 **M-15 mNGS accurately predicts mono-bacterial species in BACT/ALERT positive samples**

335 Because suboptimal sequencing yield was observed when debranched M-15 CHDD Multiple
 336 Displacement Amplification (MDA) samples were initially processed (rapid M-15) using the
 337 rapid barcoding kit (**Fig. 1**), it was decided to utilise the Ligation sequencing kit with native


338 barcodes (**Fig. 1**). Additional 27 culture (BACT/ALERT) positive BSI blood samples were
339 processed with the high-yield M-15 mNGS protocol.

340 Overall, blood-culture positive (BCP) samples subjected to CHDD had 152.4x higher DNA
341 concentration compared to culture negative (BCN) samples (BCP CHDD 509.02 ng/ μ L versus
342 BCN CHDD 3.34 ng/ μ L, as measured using Qubit) after 60 minutes MDA (**Fig. 4A, Tab. S1**).
343 However, directly extracted and amplified blood culture negative samples yielded 753 ng/ μ L
344 DNA on average following 1-hour MDA with REPLI-g kit (**Tab. S1**). Four bacterial species with
345 high GC content, *Brevibacterium luteocum* (GC 67.8%), *Micrococcus luteus* (GC 74.0%),
346 *Stenotrophomonas maltophilia* (GC 66.7%) and *Achromobacter xylosoxidans* (GC 64.0%)
347 yielded low DNA (15.7x less than other species), with an average of 32.23 ng/ μ L after 1-hour
348 MDA; however, this was still 9.64x higher than BCN samples following CHDD (**Tab. S1**). The
349 potential reason behind low yield in species with high GC% could involve stable secondary
350 structure or denaturation difficulties as highlighted in some studies [22, 23].

351 With CZ ID, using a cutoff of 20% abundance (200,000 Bases Per Million: BPM) successfully
352 removed all bacterial species identified except those detected using culture-based methods.
353 Using this cutoff, sequencing correctly identified 28/28 mono-bacterial species, 3/3 negative
354 samples and 2/4 multi-bacterial species found in two samples (**Fig. 4B, S1 A**).

355 Initially, it was assumed that the two species (*K. oxytoca* and *E. faecalis*) in two mixed samples
356 (BCP05, and BCP24) were missed due to bacterial cell lysis during CHDD (**Fig. 4B**). However,
357 some of the mono-bacterial samples tested in this study contained the same bacterial
358 genera/species and no negative bias was observed with sequencing following CHDD. Also, all
359 the CHDD flagged positive samples (n=30, species=17) were cultured overnight to confirm
360 viability, and only one (*M. luteus*) showed visible growth impairment on agar plates (**Tab. S1**).
361 Therefore, it is likely that these two organisms were missed with sequencing due to their
362 relatively low abundance compared to the other species present in the sample. For one
363 sample (BCP15), *Klebsiella pneumoniae* was identified with culture but *Klebsiella variicola*
364 with mNGS; however, the species was later confirmed to be *K. variicola* with 16S rRNA
365 amplicon sequencing. Overall, expected bacterial species constituted 88.7% of total
366 sequencing yield versus human which represented only 0.46% total DNA (**Fig. 4B**).

367



368

369 **Fig. 4: Species and antimicrobial resistance prediction accuracy of M-15 mNGS** (A) DNA
 370 concentration (ng/μL) of three blood culture negative (BCN01-BCN03) and 30 blood culture flagged
 371 positive (BCP) samples, following M-15 chemical host DNA depletion (CHDD), and whole genome
 372 amplification with the REPLI-g kit. Quantification was performed with Qubit Broad Range dsDNA assay.
 373 (B) Proportion of expected bacterial DNA (yellow bar chart; confirmed by culture) versus all other
 374 reads following M-15 CHDD and MinION sequencing with native barcoding kit. BACT/ALERT positive
 375 samples that have species-level agreement with culture have text labelled dark blue, those with
 376 genus-level agreement are purple, and those not detected by sequencing are labeled red. (C)
 377 Cumulative depth for eight Gram-positive and nine Gram-negative organisms from 30 BACT/ALERT
 378 positive blood culture samples following M-15 mNGS, with 100 Mbp sequencing yield per sample. (D)
 379 Number and proportion of true positive, true negative, false positive and false negative AMR
 380 predictions with M-15 mNGS compared to the standard culture-based AST prediction for 30
 381 BACT/ALERT positive blood culture samples. (E) Number and proportion of ResFinder true positive,
 382 true negative, false positive and false negative AMR predictions with M-15 mNGS by bacterial species

383 from the 30 BACT/ALERT positive blood culture samples tested in this study. **(F)** Number and
384 proportion of true/false AMR predictions with mNGS for the same culture-positive samples
385 categorised by antibiotics tested. Prediction of AMR profile with mNGS was done only using the
386 resistance and susceptibility results from antibiotics that were present in both phenotypic and
387 genotypic datasets (n=257).

388 To understand the breadth of coverage across the bacterial genomes with 100 Mbp
389 sequencing yield per CHDD sample, 100 Mbp fastq reads subsampled with rasusa were
390 analysed. For every 100 Mbp DNA sequenced per sample, 96.76% and 99.48% coverage could
391 be achieved with at least 1x depth for the Gram-positive and Gram-negative organisms
392 tested, respectively. For 5x and 10x depth, Gram positive organisms had a mean genome
393 coverage of 87.89% and 78.29% and Gram-negatives 95.28% and 78.38%, respectively (**Fig.**
394 **4C**). For all the 30-blood culture positive samples tested (BCP01 to BCP30), >20% abundance
395 cutoff accurately identified the present bacterial species with as low as 10 Mbp sequencing
396 yield per sample (**Fig. S1 A**).


397 **Rapid culture enrichment can facilitate same-day microbiological identification**

398 When a blood culture is flagged as positive, it contains approximately 10^7 to 10^9 bacterial
399 cells/mL of culture broth[24], which is more than the input concentration ($\geq 10^4$ CFU/mL)
400 required for the M-15 mNGS to work reliably, as observed during our initial experiments (**Fig.**
401 **2C**). This meant that a shorter culture enrichment step could further accelerate the
402 microbiological diagnosis, and M-15 mNGS could be utilised even before a sample flags
403 positive. However, given the variety of bacterial species involved in BSI and differences in their
404 growth rate, we aimed to understand the minimum incubation period required to reach that
405 threshold with a representative range of clinically important bacterial species (n=15).

406 Four of 15 bacterial species tested (*Streptococcus agalactiae*, *Acinetobacter baumannii*,
407 *Klebsiella pneumoniae* and *Escherichia coli*) reached 10^4 CFU/mL, the optimal concentration
408 for M-15 mNGS, under 6 hours of culture enrichment (**Fig. 5A**). With 8-hour incubation,
409 12/15 species reached the desired threshold of 10^4 CFU/mL. The remaining three species,
410 *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Pseudomonas aeruginosa*, were
411 slightly lagging, reaching approximately 6.04×10^3 CFU/mL on average with 8-hour enrichment.
412 All the species (15/15) tested reached/crossed the threshold under 10 hours of culture
413 enrichment (**Fig. 5A**).

414 To identify proportions of expected bacteria obtained using M-15 mNGS after 8-hour rapid
415 culture enrichment, three sterile blood culture samples and a subset of 10 bacterial species (5
416 Gram positive and 5 Gram negative, including the three slow-growing species tested earlier)
417 were selected and processed with this approach (**Fig. 5A, C**). One potential costly drawback
418 with the rapid enrichment approach could be the necessity to blindly sequence all blood
419 cultures if the positive and negative samples could not be differentiated prior to sequencing.
420 However, following CHDD and 60 minutes of MDA, the rapid culture-enriched spiked blood
421 samples (RESB, n=10) showed 28.16x higher dsDNA concentration (154.6 versus 5.49 ng/ μ L)
422 on average compared to sterile human blood enriched as negative controls (SBC, n=3),
423 providing a unique signature for the detection of positive samples prior to sequencing (**Fig.**
424 **5B, Tab. S2**).

425 Following sequencing, expected bacteria represented 89.4% of total DNA yield on average for
426 7 samples that reached 10^4 CFU/mL under 8-hours versus 50.06% for the remaining 3
427 samples having relatively slow-growing species. All samples combined, 75.4% of the total DNA
428 yield matched with the bacterial species initially used for spiking and enrichment and 17.64%
429 with host species (**Fig. 5C**). Similar to BACT/ALERT positive samples, >20% abundance
430 threshold successfully identified 10/10 bacterial species sequenced to validate the rapid
431 enrichment protocol (**Fig. 5C**). Also, like before, as low as 10 Mbp yield (subsampled) was
432 sufficient to accurately identify bacterial species with the abovementioned cutoff (**Fig. S1 B**).



433

434 **Fig. 5: Rapid culture enrichment: species covered, overall accuracy in species and antimicrobial**
 435 **resistance prediction. (A)** Time to reach 10^4 colony forming units (CFU)/mL (green line; optimal
 436 concentration for chemical host DNA depletion (CHDD) with culture-based bacterial enrichment prior
 437 to M-15 CHDD and mNGS, tested with the top 15 bacterial species causing bloodstream infection. **(B)**
 438 DNA concentration (ng/μL) of the three sterile culture-enriched blood (SBC01-SBC03) and ten rapid
 439 (8-hours) culture enriched spiked blood samples, following M-15 CHDD, and whole genome
 440 amplification with the REPLI-g kit. Quantification was performed with Qubit broad range assay. **(C)**
 441 Proportion of expected bacteria (yellow; spiked initially) versus all other reads following M-15 CHDD
 442 and MinION sequencing. Species, genus and non-agreements from rapid culture-enriched samples are
 443 highlighted with the same colored labels as before. **(D)** Number and proportion of ResFinder true
 444 positive, true negative, false positive and false negative AMR predictions with M-15 mNGS compared
 445 to the whole genome sequencing (WGS) results of the same isolates/strains. MR: methicillin-resistant

446 ***In silico* prediction of AMR is promising but requires improvement for clinical use**

447 The accuracy of AMR prediction for the BACT/ALERT positive samples was determined
 448 comparing the ResFinder phenotype antibiotic data with the phenotypic culture-based
 449 antimicrobial susceptibility testing (AST) results (n= 257). For all 30 culture positive samples,
 450 mNGS exhibited 90.32% (232/257) categorical agreement overall, with 8.49% (18/212) major
 451 error and 15.55% (7/45) very major error (Fig. 4D). Among the 17 bacterial species,

452 discrepancies in resistance calls for *K. michiganensis* (5/18), *K. pneumoniae* (6/18), and *S.*
453 *aureus* (5/18) contributed to the highest number of major errors, and *E. coli* (2/07) and *S.*
454 *epidermidis* (2/07) towards very major error (**Fig. 4E**). Of 27 antibiotics for which results were
455 compared, very major error for ciprofloxacin was most common (3/7), possibly due to the
456 relatively low accuracy of ONT reads and the frequent association of resistance to
457 fluoroquinolones with mutations in quinolone resistance determining region (QRDR) of DNA
458 gyrase and topoisomerase encoding genes, as opposed to resistance encoding gene
459 presence/absence in other antibiotics.[25] Clindamycin (4/18) and piperacillin/tazobactam
460 (3/18) were the top two antibiotics exhibiting major errors (**Fig. 4F**).

461 Due to the smaller number of ATCC strains and clinical isolates (n =10) tested, and
462 unavailability of phenotypic AST data for a few clinical isolates, AMR predictions of M-15
463 mNGS with the rapid culture method were compared to whole genome sequencing (WGS) of
464 pure bacterial strains predicted AMR of the same strains/species using ResFinder (n = 920
465 predictions). Overall categorical agreement for M-15 mNGS versus WGS was 98.7% (908/920)
466 and mNGS exhibited 89.1% true susceptible, 9.6% true resistant, 1.3% false susceptible and
467 no false resistant predictions (**Fig. 5D**). *P. aeruginosa* was the only species for which
468 sequencing results did not match perfectly with its reference genome (12/92 predictions) and
469 therefore was the only source of false susceptibility, possibly due to its high GC content
470 leading to inefficient/uneven DNA amplification with the REPLI-g kit (**Tab. S2**).

471 For both BACT/ALERT positive blood culture and rapid enriched spiked blood M-15 CHDD
472 blood, ≥ 50 Mbp sequencing yield was sufficient to predict AST profiles, with the accuracy
473 almost the same as having a sequencing yield of >100 Mbp per sample (**Fig. S2, S3**).

474 Discussion

475 Timely identification of pathogens and their antimicrobial resistance profile is crucial in BSI
476 because more targeted and effective antibiotic therapy can minimise the progression and
477 severity of the disease and therefore lead to improved patient outcomes. In addition,
478 reduced prescription of broad-spectrum antibiotics may help preserve their effectiveness,
479 limit the emergence of new antibiotic-resistant strains and protect the valuable microbiota
480 that plays an important role in maintaining overall nutrition and health [26]. Rapid
481 sequencing-based methods, especially in combination with selective chemical depletion

482 approaches, have the potential to reduce turnaround time and therefore lessen detrimental
483 outcomes. In working towards this goal, this study initially assessed the effectiveness of five
484 published and commercial, one in-house and one computation-based host depletion
485 strategies.

486 As a first step, we compared the effectiveness of an in-house host depletion method (M-15)
487 with five published and commercial approaches, as well as a computation-based host
488 depletion strategy. The host depletion efficiency of most of the CHDD workflows was
489 outstanding (particularly for M-15 and P1). However, we also noticed a correlation between
490 depletion efficiency and loss of bacterial DNA with some protocols (e.g., C2) showing
491 significant negative bias towards some species. For samples with low bacterial abundance,
492 the proportion of bacterial DNA was insignificant, $\leq 1\%$ of total DNA, even after M-15 CHDD,
493 which can remove $>99.99\%$ host DNA. However, bacteria represented $>50\%$ of total DNA
494 sequence yield for the CHDD samples containing $\geq 10^4$ CFU/mL bacteria. This meant additional
495 enrichment/depletion was necessary to get improved proportions of the sequencing yield
496 that is bacterial. As a simple and cost-effective alternative, we realised that a culture-based
497 enrichment step prior to CHDD and sequencing might improve DNA extraction
498 efficiency/robustness and proportion of bacteria in the sample simultaneously.

499 Therefore, we initially tested BACT/ALERT positive samples with two versions of M-15 mNGS
500 protocols. As confirmed during the initial phase, the proportion of host: bacterial DNA
501 sequenced was improved significantly with CHDD and AS. However, the sequencing yield was
502 suboptimal when CHDD whole genome amplification (WGA) was paired directly with the
503 Rapid Barcoding Kit (not systematically tested). The best output was observed when
504 debranched MDA products were barcoded using the Ligation Sequencing Kit, although it
505 requires additional hands-on time and potentially pricier reagents for library preparation.
506 Both versions of the workflows have their own strengths and limitations; for example, the
507 rapid workflow requires less hands-on time but may result in relatively low sequencing yield,
508 leading to higher sequencing cost per sample (**Fig. 1**). In contrast, the high-yield workflow
509 would reduce sequencing cost by providing greater output with only 90 additional minutes
510 for sample processing (**Fig. 1**). Several studies have already highlighted this difference;[27, 28]
511 consequently, users may choose the workflow that best suits their need/budget.

512 Although there are multiple bioinformatic pipelines available for mNGS-based species
513 identification, only a few have been developed/standardised for diagnosing bloodstream
514 infection. The aim of this study was therefore not to benchmark these pipelines; instead, we
515 assessed the utility of one of the well-regarded workflows, CZ ID, in combination with M-15
516 mNGS. With the 20% (200,000 BPM) abundance cutoff, sequencing accurately identified 3/3
517 negative, 28/28 mono-bacterial and 2/4 multi-bacterial species reported in two samples, with
518 >88% DNA classified as the expected species. To determine minimum sequencing yield
519 required to accurately identify bacterial species, we randomly subsampled the reads under
520 the established assumption (**Fig. 2C**) that the proportion of host: bacteria remains consistent
521 throughout a sequencing run [29]. The results demonstrated that the species prediction
522 accuracy with the given cutoff remains nearly identical even with 10 Mbp yield per sample.
523 Therefore, it is not entirely necessary to generate hundreds of Mbp reads/sample to cover
524 ~100% of the genome with >20x depth for patient management unless the aim is to utilise
525 this data for hospital outbreak investigation.

526 With the rapid culture enrichment, only a few species tested reached/crossed $\geq 10^4$ CFU/mL
527 threshold under 6 hours, and at least 8 hours of incubation was required to get more
528 comprehensive representation of critically important Gram-positive (n=7) and Gram-negative
529 (n=8) bacterial pathogens. M-15 CHDD and sequencing of a subset of rapid (8-hour) enriched
530 samples (5 Gram-positive and 5 Gram-negative) further confirmed our hypothesis: sequence
531 reads from expected bacteria represented >75% of total yield, and similar to BACT/ALERT
532 positive samples, only 10 Mbp reads accurately identified species with the previously assigned
533 abundance threshold.

534 Regarding AMR prediction, it is worth highlighting that not all expected molecular
535 mechanisms of antibiotic resistance have been determined [30]. Additionally, a mere
536 presence or absence of genes and/or mutations does not always correlate to phenotypic
537 resistance or susceptibility [30]. Therefore, at present, it is less likely that a sequencing-based
538 approach would match culture-based phenotypic results with 100% accuracy for all the
539 bacterial species commonly identified in BSI. Like species identification, several workflows can
540 predict AMR using mNGS data. The underlying principles, databases and/or accuracy can vary
541 among these workflows for AMR identification [31]. Therefore, it was decided to test
542 ResFinder, a well-regarded workflow, with M-15 mNGS, as benchmarking several

543 workflows/bioinformatic pipelines was not within the scope of this study. M-15 mNGS
544 combined with ResFinder exhibited overall 90.3% accuracy 8.49% major and 15.55% very
545 major error with BACT/ALERT positive samples. These proportions closely match with some of
546 the other studies that utilised culture enriched samples for metagenomic sequencing,
547 although very major error rates with M-15 mNGS were found to be marginally lower [20].

548 With rapid culture-enriched samples, WGS data was used as comparator. Although this is less
549 ideal than comparing with culture-based phenotypic results, we wanted to understand how
550 closely mNGS results matched those of reference sequences of bacteria that were used for
551 spiking. With 920 ResFinder AST predictions, mNGS showed 98.7% categorical agreement,
552 and only 1.3% false susceptibility, primarily due to *P. aeruginosa*, the only species exhibiting
553 discordant results. Similar suboptimal results with *P. aeruginosa* were also observed in the
554 aforementioned study [20]. However, in our case, this likely stemmed from inefficient/uneven
555 DNA amplification due to high GC content of *P. aeruginosa* (66.6%), as we did not observe any
556 lysis/viability issues with culture when CHDD samples were plated on agars (Tab. S2).

557 Considering the overall performance, it seems more work is required in terms of wet/dry lab
558 to make AMR predictions more accurate (e.g., Q30 reads and/or utilizing machine learning
559 models [32]) to be accepted as a replacement of blood culture and phenotypic assays.
560 However, as an addition to existing methods, M-15 mNGS at its current stage still holds
561 promise to inform treatment in comparison to empirical antibiotic therapy. For clinical
562 management of BSI or infection in general, the accuracy of empirical treatment can range
563 from 20% to 80% [33-35]. This means that a high proportion of cases receive inappropriate
564 antibiotics until more targeted therapy is administered utilizing the phenotypic AST results
565 (conventionally available in 48-72 hours), potentially risking detrimental outcomes for
566 critically ill patients [34]. With the rapid availability of bacterial species and AMR predictions
567 that surpass empiric prescription and therapy, mNGS can significantly refine the choice of
568 antimicrobials, increasing the likelihood of favourable outcomes. That being said, thorough
569 clinical validation would be required for rapid M-15 mNGS to be recommended for clinical
570 implementation.

571 A possible costly drawback when implementing the rapid enrichment approach was the
572 necessity to blindly sequence all blood cultures if the culture positive and negative samples
573 could not be differentiated prior to sequencing. However, when compared to the negative

574 blood samples, both BACT/ALERT positive and rapid enriched spiked M-15 CHDD blood had
575 152x and 28x higher dsDNA concentration following MDA, meaning any negative samples
576 could potentially be filtered out prior to sequencing if their Qubit-measured DNA
577 concentration provides a differentiable signature, as we observed following CHDD and WGA
578 (Tab. S1, S2). However, the exact cutoff must be determined site-wise (different clinical
579 settings or in different laboratories) with more negative patient samples before
580 implementation in a clinical setting. It is important to note that this differentiation is only
581 possible with rapid CHDD as direct extraction and amplification would not provide a
582 discernible characteristic for negative samples due to the overwhelming abundance of host
583 DNA masking the unique signature from the bacteria (Tab. S2). This approach may incorrectly
584 flag some slow growing and/or bacterial species with high GC% as negative. However,
585 because M-15 mNGS is currently intended to complement existing technologies rather than
586 replacing them, species that might be missed would still be captured with traditional culture-
587 based methods.

588 It is important to recognise that this study had several limitations. Since we only had access to
589 different volumes of surplus EDTA treated blood samples from the suspected BSI cases, stored
590 in a refrigerator for up to five days until reporting was complete, it was decided not to test the
591 rapid enrichment workflow on patient samples. Instead, 15 clinically important bacterial
592 species were chosen for initial validation. This is because the different volume and extended
593 storage of the samples might alter the host/pathogen ratio, affect viability, and/or change the
594 actual growth of the bacteria and therefore might not be an appropriate representative of
595 freshly drawn samples.

596 Also, the rapid and high yield mNGS workflows were benchmarked, and a few batches of
597 samples were initially processed using R9.4.1 flow cells, before more accurate R10.4.1 kits
598 became widely available on the market. Therefore, it was decided to continue testing all the
599 samples with library kits compatible with R9.4.1 flow cells [27]. We believe that the
600 performance of M-15 CHDD would be further enhanced with the use of newer versions of
601 kits/flow cells, as a higher proportion of \geq Q20 reads would likely allow mutations associated
602 with AMR to be more reliably predicted.

603

604 Conclusions

605 In summary, in this study, we demonstrated that M-15 CHDD paired with a rapid barcoding or
606 ligation sequencing workflow is highly effective at species and AMR gene detection in
607 BACT/ALERT positive and rapid culture enriched samples. This approach can deplete
608 significant amount of host DNA and facilitate rapid bacterial/AMR identification, with a hands-
609 on time of less than 4 (rapid barcoding kit) and 6 hours (ligation sequencing kit), plus time
610 required to generate 10 Mbp (species)/ ≥ 50 Mbp (AMR) sequencing yield per sample. The
611 time to achieve this yield can vary depending on the capacity of the flow cells used and/or the
612 number of samples multiplexed in a sequencing run, therefore, it is up to the user to choose
613 the appropriate flow cell and/or number of samples based on their needs. However, we
614 demonstrated that with 8-hour culture enrichment, M-15 mNGS can predict causative
615 bacterial species and accurately detect AMR determinants within 13-15 hours of sample
616 collection, and thus has the potential to improve patient outcomes in BSI.

617

618

619

620

621

622

623

624

625

626

627

628

629

630 **Abbreviations**

631 AMR: Antimicrobial resistance

632 AS: Adaptive sampling

633 AST: Antimicrobial susceptibility testing

634 ATCC: American Type Culture Collection

635 BSI: Bloodstream infection

636 BPM: Bases per million

637 CFU: Colony-forming units

638 CHDD: Chemical host DNA depletion

639 dsDNA: Double-stranded DNA

640 EUCAST: European Committee on Antimicrobial Susceptibility Testing

641 FDA: Food and Drug Administration (USA)

642 GC%: Guanine-cytosine content percentage

643 mNGS: Metagenomic next-generation sequencing

644 Mbp: Megabase pairs

645 MDA: Multiple displacement amplification

646 NHS: National Health Service (UK)

647 ONT: Oxford Nanopore Technologies

648 PBS: Phosphate-buffered saline

649 qPCR: Quantitative polymerase chain reaction

650 RBC: Red blood cells

651 WGA: Whole-genome amplification

652 WGS: Whole-genome sequencing

653 **Funding**

654 This study was funded by Royal Society Research Grant (RGS\R1\211163) and University of
655 Glasgow's Lord Kelvin Adam Smith (LKAS) Ph.D. studentship.

656 **Ethical statement**

657 This study was reviewed and approved by the University of Glasgow College of Medical,
658 Veterinary & Life Sciences Ethics Committee (Project No: 200210015) and UK National Health
659 Services (NHS) Greater Glasgow and Clyde (R&I reference: GN19ID331). No personal
660 information from the patients and healthy volunteers was collected and used in this study.
661 Human DNA reads obtained from mNGS were excluded or not utilised for any bioinformatics
662 analyses beyond quantifying the number of hosts reads generated.

663 **Availability of data and materials**

664 All the raw sequencing reads (fastq.gz: host excluded) analysed and presented in this study
665 are available on European Nucleotide Archive under the study accession "PRJEB80726".

666 **Authors' contributions**

667 Conceptualisation of this study was carried out by TF and MSIS. Data generation, cleaning,
668 management, formal analysis, and initial draft was written by MSIS. Project investigation,
669 experimental method selection, clinical sample collection, formal review and coordination
670 was done by TF, KB, KO, PE, MEM, CW, MF, and MSIS. TF (RS) and MSIS (LKAS) acquired
671 funding for this project.

672 **Acknowledgements**

673 We would like to thank Kareen Macleod for generously providing the reference isolates used
674 in this study. We also want to express our gratitude to Ryan Carter and Angelo Mendes for
675 their help and input on this project.

676

677

678


679 **References**

- 680 1. Ikuta KS, Lucien R. Swetschinski, Gisela R. Aguilar, Fablina Sharara, Tomislav Mestrovic,
681 Authia P. Gray, Nicole D. Weaver: **Global mortality associated with 33 bacterial**
682 **pathogens in 2019: a systematic analysis for the Global Burden of Disease Study**
683 **2019.** *Lancet* 2022, **400**:2221-2248.
- 684 2. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-
685 Loeches I, Leone M, Lupu MN, Vincent JL, Investigators I: **Sepsis in Intensive Care Unit**
686 **Patients: Worldwide Data From the Intensive Care over Nations Audit.** *Open Forum*
687 *Infect Dis* 2018, **5**:ofy313.
- 688 3. Tabak YP, Vankeepuram L, Ye G, Jeffers K, Gupta V, Murray PR: **Blood Culture**
689 **Turnaround Time in U.S. Acute Care Hospitals and Implications for Laboratory**
690 **Process Optimization.** *J Clin Microbiol* 2018, **56**:10-1128.
- 691 4. Paharik AE, Schreiber HLT, Spaulding CN, Dodson KW, Hultgren SJ: **Narrowing the**
692 **spectrum: the new frontier of precision antimicrobials.** *Genome Med* 2017, **9**:110.
- 693 5. Chiu CY, Miller SA: **Clinical metagenomics.** *Nature Reviews Genetics* 2019, **20**:341-
694 355.
- 695 6. Charalampous T, Kay GL, Richardson H, Aydin A, Baldan R, Jeanes C, Rae D, Grundy S,
696 Turner DJ, Wain J, et al: **Nanopore metagenomics enables rapid clinical diagnosis of**
697 **bacterial lower respiratory infection.** *Nat Biotechnol* 2019, **37**:783-792.
- 698 7. Trung NT, Hien TT, Huyen TT, Quyen DT, Van Son T, Hoan PQ, Phuong NT, Lien TT, Binh MT,
699 Van Tong H, et al: **Enrichment of bacterial DNA for the diagnosis of blood stream**
700 **infections.** *BMC Infect Dis* 2016, **16**:235.
- 701 8. Marotz CA, Sanders JG, Zuniga C, Zaramela LS, Knight R, Zengler K: **Improving saliva**
702 **shotgun metagenomics by chemical host DNA depletion.** *Microbiome* 2018, **6**:1-9.
- 703 9. Heravi FS, Zakrzewski M, Vickery K, Hu H: **Host DNA depletion efficiency of**
704 **microbiome DNA enrichment methods in infected tissue samples.** *J Microbiol*
705 *Methods* 2020, **170**:105856.
- 706 10. McQuillan JS, Wilson MW: **'Ready Mixed', improved nucleic acid amplification assays**
707 **for the detection of Escherichia coli DNA and RNA.** *J Microbiol Methods* 2019,
708 **165**:105721.
- 709 11. Lee CS, Wetzel K, Buckley T, Wozniak D, Lee J: **Rapid and sensitive detection of**
710 **Pseudomonas aeruginosa in chlorinated water and aerosols targeting gyrB gene**
711 **using real-time PCR.** *J Appl Microbiol* 2011, **111**:893-903.
- 712 12. Wood C, Sahl J, Maltinsky S, Coyne B, Russakoff B, Yague DP, Bowers J, Pearson T:
713 **SaQuant: a real-time PCR assay for quantitative assessment of Staphylococcus**
714 **aureus.** *BMC Microbiol* 2021, **21**:174.
- 715 13. Bohl JA, Lay S, Chea S, Ah Yong V, Parker DM, Gallagher S, Fintzi J, Man S, Ponce A, Sreng
716 S, et al: **Discovering disease-causing pathogens in resource-scarce Southeast Asia**
717 **using a global metagenomic pathogen monitoring system.** *Proc Natl Acad Sci U S A*
718 2022, **119**:e2115285119.
- 719 14. Miles AA, Misra SS, Irwin JO: **The estimation of the bactericidal power of the blood.** *J*
720 *Hyg (Lond)* 1938, **38**:732-749.
- 721 15. Nurk S, Koren S, Rhie A, Rautiainen M, Bzikadze AV, Mikheenko A, Vollger MR, Altemose
722 N, Uralsky L, Gershman A, et al: **The complete sequence of a human genome.** *Science*
723 2022, **376**:44-53.
- 724 16. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe
725 RL, Rebelo AR, Florensa AF, et al: **ResFinder 4.0 for predictions of phenotypes from**
726 **genotypes.** *J Antimicrob Chemother* 2020, **75**:3491-3500.
- 727 17. Li H: **Minimap2: pairwise alignment for nucleotide sequences.** *Bioinformatics* 2018,
728 **34**:3094-3100.


- 729 18. Hall M: **Rasusa: Randomly subsample sequencing reads to a specified coverage.**
730 *Journal of Open Source Software* 2022, **7**:3941.
- 731 19. Giske CG, Turnidge J, Canton R, Kahlmeter G, Committee ES: **Update from the**
732 **European Committee on Antimicrobial Susceptibility Testing (EUCAST).** *J Clin*
733 *Microbiol* 2022, **60**:e0027621.
- 734 20. Harris PNA, Bauer MJ, Lueftinger L, Beisken S, Forde BM, Balch R, Cotta MO,
735 Schlapbach L, Raman S, Shekar K: **Rapid nanopore sequencing and predictive**
736 **susceptibility testing of positive blood cultures from intensive care patients with**
737 **sepsis.** *Microbiology spectrum* 2024, **12**:e03065-03023.
- 738 21. Huang TH, Tzeng YL, Dickson RM: **FAST: Rapid determinations of antibiotic**
739 **susceptibility phenotypes using label-free cytometry.** *Cytometry A* 2018, **93**:639-648.
- 740 22. Ospino MC, Engel K, Ruiz-Navas S, Binns WJ, Doxey AC, Neufeld JD: **Evaluation of**
741 **multiple displacement amplification for metagenomic analysis of low biomass**
742 **samples.** *ISME Commun* 2024, **4**:ycae024.
- 743 23. Sobol MS, Kaster AK: **Back to Basics: A Simplified Improvement to Multiple**
744 **Displacement Amplification for Microbial Single-Cell Genomics.** *Int J Mol Sci* 2023,
745 **24**:4270.
- 746 24. Wang MC, Lin WH, Yan JJ, Fang HY, Kuo TH, Tseng CC, Wu JJ: **Early identification of**
747 **microorganisms in blood culture prior to the detection of a positive signal in the**
748 **BACTEC FX system using matrix-assisted laser desorption/ionization-time of flight**
749 **mass spectrometry.** *J Microbiol Immunol Infect* 2015, **48**:419-424.
- 750 25. Neyestani Z, Khademi F, Teimourpour R, Amani M, Arzanlou M: **Prevalence and**
751 **mechanisms of ciprofloxacin resistance in Escherichia coli isolated from**
752 **hospitalized patients, healthy carriers, and wastewaters in Iran.** *BMC Microbiol*
753 2023, **23**:191.
- 754 26. Valdes AM, Walter J, Segal E, Spector TD: **Role of the gut microbiota in nutrition and**
755 **health.** *BMJ* 2018, **361**:k2179.
- 756 27. Ni Y, Liu X, Simeneh ZM, Yang M, Li R: **Benchmarking of Nanopore R10.4 and R9.4.1**
757 **flow cells in single-cell whole-genome amplification and whole-genome shotgun**
758 **sequencing.** *Comput Struct Biotechnol J* 2023, **21**:2352-2364.
- 759 28. ONT: **Premium whole genome amplification-Oxford Nanopore Technologies.**
760 **Ligation sequencing gDNA. SQK-LSK109.** 2022.
- 761 29. Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R: **Rapid identification of pathogens,**
762 **antibiotic resistance genes and plasmids in blood cultures by nanopore**
763 **sequencing.** *Sci Rep* 2020, **10**:7622.
- 764 30. Su M, Satola SW, Read TD: **Genome-Based Prediction of Bacterial Antibiotic**
765 **Resistance.** *J Clin Microbiol* 2019, **57**:10.1128/jcm. 01405-01418.
- 766 31. Doyle RM, O'Sullivan DM, Aller SD, Bruchmann S, Clark T, Coello Pelegrin A, Cormican
767 M, Diez Benavente E, Ellington MJ, McGrath E, et al: **Discordant bioinformatic**
768 **predictions of antimicrobial resistance from whole-genome sequencing data of**
769 **bacterial isolates: an inter-laboratory study.** *Microb Genom* 2020, **6**:e000335.
- 770 32. Ali T, Ahmed S, Aslam M: **Artificial Intelligence for Antimicrobial Resistance**
771 **Prediction: Challenges and Opportunities towards Practical Implementation.**
772 *Antibiotics (Basel)* 2023, **12**:523.
- 773 33. Marquet K, Liesenborgs A, Bergs J, Vleugels A, Claes N: **Incidence and outcome of**
774 **inappropriate in-hospital empiric antibiotics for severe infection: a systematic**
775 **review and meta-analysis.** *Crit Care* 2015, **19**:1-12.
- 776 34. Kadri SS, Lai YL, Warner S, Strich JR, Babiker A, Ricotta EE, Demirkale CY, Dekker JP,
777 Palmore TN, Rhee C, et al: **Inappropriate empirical antibiotic therapy for**
778 **bloodstream infections based on discordant in-vitro susceptibilities: a**

779 **retrospective cohort analysis of prevalence, predictors, and mortality risk in US**
780 **hospitals. *Lancet Infect Dis* 2021, 21:241-251.**
781 35. Luo Y, Guo Z, Li Y, Ouyang H, Huang S, Chen Y, Li K, Ji Y, Zhu H, Luo W, et al:
782 **Appropriateness of Empirical Antibiotic Therapy in Hospitalized Patients with**
783 **Bacterial Infection: A Retrospective Cohort Study. *Infect Drug Resist* 2023, 16:4555-**
784 **4568.**
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800

801 Supplementary Figures, tables and protocols



802
803 **Fig. S1: Accuracy of species prediction with varying sequencing yield (100 Mbp to 10 Mbp),**
804 identified by subsampling the (A) reads from 17 bacterial species from the 30 BACT/ALERT positive
805 blood culture samples and (B) 10 rapid (8-hours) culture enriched spiked blood samples. Analysis was
806 performed similarly using CZ ID with the same abundance threshold for all the species tested. Colored
807 gradient highlights the species that passed the initial threshold filter and their abundance (base per
808 million) in the CHDD samples that were sequenced.



822

823 **Fig. S3: Antibiotic susceptibility profiles predicted with varying sequencing yield (>50 Mbp to 10**
 824 **Mbp/sample) using the subsampled reads from 10 rapid culture enriched (8-hours) spiked blood**
 825 **samples. (A) The heatmap shows antimicrobial resistance profiles and (B) the barplot highlights the**
 826 **number of antimicrobials from different antibiotic classes identified with different sequencing yield for**
 827 **rapid culture enriched spiked blood samples.**

828

829

830

831

832

833 **Tab. S1:** Double stranded DNA concentration of three BACT/ALERT negative (BCN01 to BCN03) and 30
 834 BACT/ALERT positive blood culture (BCP) samples quantified by Qubit following M-15 CHDD and 60
 835 minutes of multiple displacement amplification with REPLI-g kit. As controls, six samples (BCN01 to
 836 BCN03 and BCP01 to BCP03) were also extracted directly and amplified similarly for 60 minutes
 837 without CHDD. Viability of bacterial following M-15 CHDD was confirmed by plating the supernatant
 838 on nutrient and blood agar media.

Sample	Accession	Organism	Culture	GC content (%)	Viability after M-15 CHDD	CHDD samples DNA (ng/μL)	No-CHDD samples DNA (ng/μL)
BCN01	ERR13759391	Not detected	Negative	N/A	N/A	1.6	733
BCN02	ERR13759392	Not detected	Negative	N/A	N/A	2.8	767
BCN03	ERR13759393	Not detected	Negative	N/A	N/A	5.5	760
BCP01	ERR13759394	<i>S. pyogenes</i>	Positive	38.5	Viable	209	490
BCP02	ERR13759395	<i>S. aureus</i>	Positive	32.8	Viable	201	920
BCP03	ERR13759396	<i>E. coli</i>	Positive	50.8	Viable	350	940
BCP04	ERR13759397	<i>S. pyogenes</i>	Positive	38.5	Viable	291	Not tested
BCP05	ERR13759398	<i>S. epidermidis</i>	Positive	33.0	Viable	950	Not tested
BCP06	ERR13759399	<i>S. epidermidis</i>	Positive	33.0	Viable	620	Not tested
BCP07	ERR13759400	<i>B. luteolum</i>	Positive	67.8	Viable	17.4	Not tested
BCP08	ERR13759401	<i>M. luteus</i>	Positive	74.0	Not viable	9.44	Not tested
BCP09	ERR13759402	<i>P. mirabilis</i>	Positive	38.8	Viable	235	Not tested
BCP10	ERR13759403	<i>S. agalactiae</i>	Positive	35.5	Viable	77.8	Not tested
BCP11	ERR13759404	<i>E. coli</i>	Positive	50.8	Viable	1480	Not tested
BCP12	ERR13759405	<i>E. coli</i>	Positive	50.8	Viable	342	Not tested
BCP13	ERR13759406	<i>K. michiganensis</i>	Positive	55.5	Viable	1390	Not tested
BCP14	ERR13759407	<i>E. coli</i>	Positive	50.8	Viable	843	Not tested
BCP15	ERR13759408	<i>K. variicola</i>	Positive	57.3	Viable	1340	Not tested
BCP16	ERR13759409	<i>S. agalactiae</i>	Positive	35.5	Viable	325	Not tested
BCP17	ERR13759410	<i>L. adecarboxylata</i>	Positive	52.55	Viable	111	Not tested
BCP18	ERR13759411	<i>E. coli</i>	Positive	50.8	Viable	1170	Not tested
BCP19	ERR13759412	<i>S. aureus</i>	Positive	32.8	Viable	326	Not tested
BCP20	ERR13759413	<i>S. maltophilia</i>	Positive	66.7	Viable	18.1	Not tested
BCP21	ERR13759414	<i>S. epidermidis</i>	Positive	33.0	Viable	440	Not tested
BCP22	ERR13759415	<i>E. faecalis</i>	Positive	37.5	Viable	432	Not tested
BCP23	ERR13759416	<i>K. pneumoniae</i>	Positive	57.3	Viable	680	Not tested
BCP24	ERR13759417	<i>P. mirabilis</i>	Positive	38.7	Viable	860	Not tested
BCP25	ERR13759418	<i>E. coli</i>	Positive	50.8	Viable	1033	Not tested
BCP26	ERR13759419	<i>S. gallolyticus</i>	Positive	37.69	Viable	297	Not tested
BCP27	ERR13759420	<i>S. aureus</i>	Positive	32.8	Viable	228	Not tested
BCP28	ERR13759421	<i>A. xylosoxidans</i>	Positive	64.0	Viable	84	Not tested
BCP29	ERR13759422	<i>S. epidermidis</i>	Positive	33.0	Viable	406	Not tested
BCP30	ERR13759423	<i>C. jejuni</i>	Positive	30.3	Viable	348	Not tested

840 **Tab. S2:** Double stranded DNA concentration of three 8-hour culture enriched sterile blood (HB1 to
841 HB3) versus ten spiked blood (1-10 CFU) samples following 60 minutes of multiple displacement
842 amplification with REPLI-g kit with and without M-15 chemical host DNA depletion (CHDD) measured
843 by Qubit. Viability of bacteria following M-15 CHDD was confirmed by plating the supernatant on
844 nutrient and blood agars.

Sample	Organism	Culture	GC content (%)	Viability after M-15 CHDD	CHDD samples DNA (ng/ μ L)	No-CHDD samples DNA (ng/ μ L)
HB1	Not detected	Negative	NA	N/A	4.2	652
HB2	Not detected	Negative	NA	N/A	8.1	487
HB3	Not detected	Negative	NA	N/A	4.18	513
RESB1	<i>S. aureus</i>	Positive	32.8	Viable	131	510
RESB2	<i>E. faecium</i>	Positive	37.8	Viable	122	611
RESB3	<i>S. pyogenes</i>	Positive	38.5	Viable	140	377
RESB4	<i>S. agalactiae</i>	Positive	35.6	Viable	177	647
RESB5	<i>S. pneumoniae</i>	Positive	39.7	Not viable	83	550
RESB6	<i>P. aeruginosa</i>	Positive	66.6	Viable	43	449
RESB7	<i>K. quasipneumoniae</i>	Positive	57.2	Viable	213	714
RESB8	<i>A. baumannii</i>	Positive	39	Viable	156	699
RESB9	<i>E. coli</i>	Positive	50.8	Viable	248	892
RESB10	<i>P. mirabilis</i>	Positive	38.88	Viable	233	621

845

846

847

848

849

850

851

852

853

854

855

856

857

858

859

860

861

862 **Tab. S3:** AMR gene profile (genes expected based on whole genome sequencing data) of the 8-hour
863 culture-enriched blood samples chosen for sequencing (n=10). Following M-15 mNGS, sequencing
864 reads were analysed with ResFinder to match and confirm the presence/absence of the same AMR
865 determinants expected from the species initially utilised for spiking. Prediction accuracy of AMR
866 (Match%) was determined comparing the ResFinder predicted phenotypic AST results of M-15 mNGS
867 versus previously sequenced clinical/ATCC strains.

Sample	Accession	Organism	Source	Genes expected	Genes found (M-15)	Gene Match	Phenotype Match (%)
RESBO 1	ERR13759428	<i>S. aureus</i>	NCTC 12493	<i>mecA, ant(9)-Ia, erm(A), tet(K)</i>	<i>mecA, ant(9)-Ia, erm(A), tet(K)</i>	4/4	100
RESBO 2	ERR13759429	<i>E. faecium</i>	Clinical isolate	<i>aac(6)-II, ant(6)-Ia, aph(3)-III, aph(2)-Id, erm(B), msr(C), lsa(E), tet(M)</i>	<i>aac(6)-II, ant(6)-Ia, aph(3)-III, aph(2)-Id, erm(B), msr(C), lsa(E), tet(M)</i>	8/8	100
RESBO 3	ERR13759430	<i>S. pyogenes</i>	Clinical isolate	-	-	0/0	100
RESBO 4	ERR13759431	<i>S. agalactiae</i>	Clinical isolate	<i>mre(A)</i>	<i>mre(A)</i>	1/1	100
RESBO 5	ERR13759432	<i>S. pneumoniae</i>	ATCC 6303	-	-	0/0	100
RESBO 6	ERR13759433	<i>P. aeruginosa</i>	ATCC 27853	<i>aph(3)-IIb, blaPAO, blaOXA-396, fosA, catB7, crpP</i>	<i>catB7, crpP</i>	6/2	86.9
RESBO 7	ERR13759434	<i>K. quasipneumoniae</i>	ATCC 700603	<i>ant(2)-Ia, blaOKP-B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1</i>	<i>ant(2)-Ia, blaOKP-B, blaSHV-18, blaOXA-2, fosA, OqxA, OqxB, sul1</i>	8/8	100
RESBO 8	ERR13759435	<i>A. baumannii</i>	Clinical isolate	<i>blaOXA-343, blaADC-25</i>	<i>blaOXA-343, blaADC-25</i>	2/2	100
RESBO 9	ERR13759436	<i>E. coli</i>	Clinical isolate	<i>aph(3)-Ib, aph(6)-Id, blaTEM-1C, sul2</i>	<i>aph(3)-Ib, aph(6)-Id, blaTEM-1C, sul2</i>	4/4	100
RESB1 0	ERR13759437	<i>P. mirabilis</i>	Clinical isolate	<i>tet(J)</i>	<i>tet(J)</i>	1/1	100

868

869

870

871

872

873

874

875

876

877

878

879

880 **Tab. S4:** Primer, probe sequences and their reaction concentrations used in this study for detecting
 881 universal 16S (bacteria) and 18S Ribosomal ribonucleic acid-rRNA (host) genes and species-specific
 882 genes to identify three bacterial species, (*Escherichia coli* (EC), *Pseudomonas aeruginosa* (PA), and
 883 *Staphylococcus aureus* (SA)) used for initial spiking and benchmarking experiments.

Genes	Primer/Probe name	Primer/Probe Conc (nM)	Sequence (5'-3')	Reference
16S rRNA	16S rRNA_341_F	400	CCTACGGGAGGCAGCAG	Heravi et al [9].
	16S rRNA_534_R		ATTACCGCGCTGCTGG	
	16S rRNA_P	100	FAM-CCGCGTGWRTGAWGAAGGYCTTCG-BHQ1	This study
18S rRNA	18S rRNA_756_F	400	GGTGGTGCCCTTCCGTCA	Heravi et al [9].
	18S rRNA_877_R		CGATGCGGCGGCGTTATT	
	18S rRNA_P	100	Hex- ACCCAAAGACTTTGGTTCCCGGA- BHQ1	This study
EC_ybbW	EC_ybbW_F	80	TGATTGGCAAATCTGGCCG	McQuillan et al [10].
	EC_ybbW_R		GAAATCGCCCAAATCGCCAT	
	EC_ybbW_P	40	FAM-CCGCCGAAAACGATATAGATGCACGG- BHQ1	
PA_GB722	PA_GB722_F	500	GGCGTGGGTGTGGAAGTC	Lee et al [11].
	PA_GB722_R		TGGTGAAGCAGAGCAGTTCT	
	PA_GB722_P	250	FAM-TGCAGTGAACGACA- BHQ1	
SA_SaQuant	SA_SaQuant_F	1000	AACTACTAGGGGAGCCTAATRAT	Wood et al [12].
	SA_SaQuant_R		GGTACTAACCAAATCAGTCCATAA	
	SA_SaQuant_P	200	FAM-TGGCTGAGATGAAYTGTTCCAGACCC- BHQ1	

884
 885
 886
 887
 888
 889
 890
 891
 892
 893
 894
 895
 896
 897
 898
 899

900 Supplement Protocol: M-15 mNGS

901 Consumables

Name	Concentration/units	Commercial source	Comments
Saponin	Final concentration 2.25%	Tokyo chemical industry, Cat: S0019	To make a 4.5% or 2.25% w/v solution, dissolve 4.5/2.25 grams of Saponin into 50 ml sterile nuclease free H ₂ O. Mix thoroughly until dissolved. Adjust the volume to 100ml. Sterilize using 0.2 μm filter, and store at 4 °C for up to 3 weeks
NaCl	5M	Promega, Cat: V4221	NA
DNase I	300 units/μL	Invitrogen, Cat: 18047019	NA
DNase I buffer	10x solution	NEB, Cat: B0303SVIAL	10x buffer = 10 mM Tris HCl, 2.5 mM MgCl ₂ , 0.5 mM CaCl ₂
Trypsin-EDTA	0.05%, phenol red	ThermoFisher Cat: 25300054	NA
Molecular grade H ₂ O	NA	Qiagen, Cat: 129114	NA
DPBS	1x solution	ThermoFisher Cat: 14190144	Without calcium, magnesium, or phenol
T7 Endonuclease I	NA	NEB, Cat: M0302S or M0302L	NA
DNA binding beads	NA	Aline biosciences, Cat: C-1003-50	NA
Molecular grade ethanol	NA	Sigmaaldrich, Cat: 51976-500ML-F	NA

Name	Concentration/units	Commercial source	Comments
REPLI-g Single Cell Kit	NA	Qiagen, Cat: 150343 or 150345	NA
Qubit dsDNA Be assay Kit	NA	ThermoFisher, Cat: Q32853	NA
Qubit assay tubes	NA	ThermoFisher, Cat: Q32856	NA
Rapid Barcoding Kit	NA	ONT, Cat: SQK-RBK004	Required for the rapid sequencing protocol
Long Fragment Buffer Expansion	NA	ONT, Cat: EXP-LFB001	Required for the rapid sequencing protocol
Ligation Sequencing Kit	NA	ONT, Cat: SQK-LSK109	Required for the high yield protocol
Native Barcoding Expansion Kit	NA	ONT, Cat: EXP-NBD196	Required for the high yield protocol
NEBNext Ultra II End Repair/dA-Tailing Module	NA	NEB, Cat: E7546L	Required for the high yield protocol
Blunt/TA Ligase Master Mix	NA	NEB, Cat: M0367L	Required for the high yield protocol
NEBNext Quick Ligation Module	NA	NEB, Cat: E6056L	Required for the high yield protocol
Flow Cell Priming Kit	NA	ONT, Cat: EXP-FLP002	Required for both protocols
Flow Cell Wash Kit	NA	ONT, Cat: EXP-WSH004	Required for both protocols
ONT Flow Cell R9.4.1	NA	ONT, Cat: FLO-MIN106 or FLO-FLG001	Required for both protocols
Magnetic rack/plate holder	NA	ThermoFisher, Cat: 12331D and 12321D	NA

Name	Concentration/units	Commercial source	Comments
PCR Tube Strip with Attached Flat Caps	NA	ThermoFisher, Cat: AB2000	NA
1.5 ml DNA LoBind tubes	NA	Eppendorf, Cat: 0030108051-250EA	Use LoBind tubes
2 ml round bottom tubes	NA	Starlab, Cat: S1620-2700-C or Eppendorf, Cat: 0030120094	Avoid using LoBind tubes
Pipettes and pipette tips P2, P10, P20, P100, P200, P1000, Multichannel	NA	Any	NA
Centrifuge /Microplate centrifuge	NA	Any	NA
Vortex mixer	NA	Any	NA
Thermal cycler	NA	Any	NA
Heating block for 1.5/2 mL tubes	NA	Any	NA
Sequencing device	NA	Flongle, MinION Mk1B, GridION	NA
Device for live basecalling	NA	GridION or A powerful laptop	A laptop with minimum 8 Gb GPU (RTX 3060 or higher), 16 GB Ram, 1 Tb M.2 NVMe SSD

902 **Disclaimer:** Some parts of the following protocol has been copied directly from the
903 manufacturer's official website or from the kit manual. Therefore, all the proprietary
904 information mentioned below remains the sole property of the kits manufacturer.

905

906 Before sample preparation

907 It is important to divide all reagents into smaller aliquots to avoid multiple freeze-thaw cycles
908 and reduce the likelihood of cross-contamination.

909 Warm up 0.05% trypsin EDTA at 37°C. Prepare 1x DNase I buffer and store in the fridge
910 before use. Make a fresh batch of REPLI-g Master Mix following manufacturer's instructions.
911 Take out aliquots of Buffer D2, Stop Solution, and any other reagents from the freezer, and
912 store in the refrigerator or on ice until needed. Thaw all the reagents at room temperature or
913 on ice as per manufacturers recommendation.

914 This protocol can be used on BD BACTEC (Becton, Dickinson and Company, NJ, USA) or any
915 blood culture (FPBC) samples flagged positive with an automated culture system. Protocol M-
916 15 mNGS can also be applied to rapid culture enriched blood samples (REBC; for example, 1-
917 10 mL patient blood samples incubated for 8 hours in BD BACTEC media bottles), once the
918 enriched samples have at least 10^3 CFU/mL bacterial concentration. FPBC samples can be
919 used directly for CHDD; however, REBC samples need to be pre-processed to concentrate the
920 sample before continuing with this protocol. It is crucial to use fresh samples for CHDD, as
921 frozen or improperly stored samples can lead to the lysis of bacterial cells. This may lead to a
922 considerable loss of bacterial DNA during CHDD.

923 Pre-processing REBC samples

924 Transfer 1.5 mL REBC samples aseptically to a 2 mL round bottom microcentrifuge tube and
925 spin at 8,000xg for 5 minutes. Slowly aspirate the supernatant without disturbing the pellet
926 and gently resuspend the pellet in 800 μ L 2.25% saponin. Proceed to the step 2 of CHDD
927 protocol below.

928 Note* It is important to use round/wide bottom 2 mL microcentrifuge tubes to minimize bacterial cell loss while
929 aspirating the supernatant during the initial washing steps.

930

931

932

933 Host depletion

934 1. Add 400 μ L FPBC sample to 400 μ L 4.5% saponin (final saponin concentration will be 2.25%
935 after mixing) in a 2 mL wide bottom sterile microcentrifuge tube and gently pipette mix for at
936 least 4 to 5 times.

937 2. Add 1 μ L DNase I (300 units/ μ L) to the REBC/FPBC sample, pulse vortex at low speed for 5
938 seconds and incubate the sample at 25°C in a heating block for 10 minutes at 800 rpm.

939 Note* Adding DNase I decreases the viscosity of the sample by degrading a substantial amount of DNA
940 (desirably from the host) after selective host cell lysis. The DNA released from the host cells can be extremely
941 sticky, and often adhere to pipette tips or microfuge tubes. As a result, there's a risk of losing desired/targeted
942 bacterial cells because they might adhere to the sticky host DNA and get affixed to the pipette tips and/or
943 microcentrifuge tube.

944 3. Perform a quick spin and add 800 μ L molecular grade water to the sample. Pipette mix 4 to
945 5 times and incubate for 1 minute at room temperature.

946 4. Add 44 μ L 5 M molecular grade NaCl (final concentration is 137 mM; same as PBS) to the
947 sample, invert the tubes 3 to 4 times to mix and centrifuge at 10,000x g for 5 minutes.

948 5. Carefully remove the supernatant without touching or disturbing the pellet and resuspend
949 in 1 mL molecular grade 1x Dulbecco's Phosphate Buffered Saline (DPBS, Without calcium,
950 magnesium, or phenol).

951 6. Centrifuge the sample at 10,000x g for 3 minutes and carefully remove the supernatant
952 without touching or disturbing the pellet.

953 7. Resuspend the pellet in 398 μ L 1x DNase I buffer, add 2 μ L DNase I (300 units/ μ L) to the
954 sample and incubate at 37°C with shaking at 800 RPM for 15 minutes.

955 8. Following incubation, add 1 mL 0.05% trypsin EDTA directly to the sample, pipette mix at
956 least 8 to 10 times and incubate at room temperature for 1 minute.

957 Note* Some bacterial cells may form aggregates in the sample, so adding 0.05% trypsin EDTA can separate the
958 cells and ensure an even distribution for subsequent procedures. The trypsinisation step does not affect
959 bacterial viability and/or cell wall integrity.

960 9. Repeat step 6 and resuspend the pellet in 1 mL 1x DPBS.

961 Note* This is the end of host depletion with M-15. After this, 4 μL of host depleted bacterial cell material in
962 DPBS from step 9 can be used directly for alkaline lysis and whole genome amplification (WGA; protocol 1) using
963 the REPLI-g Single Cell Kit.

964 DNA extraction and Whole Genome Amplification

965 10. Prepare sufficient Buffer D2 in a PCR tube for the total number of 12 reactions.

Reagent	Volume (μL)
DTT, 1M	3
Buffer DLB	33
Total	36

966 Note* Buffer D2 should not be stored longer than 2 months at -20°C .

967 11. Place 4 μL cell material into a PCR tube containing 3 μL buffer D2. Mix by flicking the tube
968 and centrifuge briefly.

969 12. Incubate at 65°C for 10 min with heated lid on and then add 3 μL Stop Solution. Mix by
970 flicking the tube and centrifuge briefly. Prepare a master mix according to the instruction
971 below.

Reagent	Volume (μL)
REPLI-g sc Reaction Buffer	14
REPLI-g sc DNA Polymerase	1
Total	15

972 Note* Avoid using H_2O for preparing the master mix.

973 13. For each reaction, add 5 μL DNA from step 12 and incubate at 30°C for 1 hour with
974 heated lid off.

975 14. Inactivate REPLI-g sc DNA Polymerase by heating the sample for 3 min at 65°C with
976 heated lid on.

977 Note* After this step amplified host depleted DNA can be diluted 5-fold in molecular grade H_2O , measured with
978 Qubit Br assay and used directly for debranching and subsequently sequencing library preparation.

979 Debranching and bead cleanup

980 15. In a clean 0.2 mL PCR tube, mix the reagents for debranching in the following order.

981

Reagent	Volume (μL)
600 ng of amplified DNA	To make 30 μL
NEBuffer 2	3
T7 Endonuclease I	1.5
Nuclease free H ₂ O	25.5- To make 30 μL
Total	30

982 16. Mix the reagents by flicking the tube and centrifuge briefly. Incubate the reaction for 10
983 minutes at 37°C.

984 17. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.

985 18. Add 15 μL of the bead suspension (0.5x) to the DNA sample and mix by pipetting.

986 19. Incubate for 5 minutes at room temperature.

987 20. Spin down and pellet the sample on a magnetic rack/plate until supernatant is clear and
988 colourless. Keep the tube on the magnet, and pipette off the supernatant.

989 21. Keeping the tube on the magnet, wash the beads with 200 μL of freshly prepared 70%
990 ethanol without touching/disturbing the pellet. Remove the ethanol carefully using a
991 pipette and discard.

992 22. Repeat the previous ethanol washing step.

993 23. Spin down and put the tube back on the magnetic rack/plate. Pipette off any residual
994 ethanol. Open the lid and allow the tubes to dry for ~30 seconds, but do not dry the
995 pellet to the point of cracking.

996 24. Remove the tube from the magnetic rack/plate and resuspend the pellet in 15 μL
997 nuclease-free water. Incubate for 2 min at room temperature.

998 25. Pellet the beads on a magnet until the eluate is clear and colourless.

999 26. Remove and retain 12 μL of eluate into a clean 0.2 mL PCR tube.

1000 Note* This is the end of debranching and DNA cleanup. After this step, cleaned and debranched DNA products
1001 can be used for library preparation with Rapid Barcoding (rapid but low yield) or Ligation sequencing kit (highest
1002 yield).

1003

1004 **Rapid barcoding (low-medium yield protocol)**

1005 **Barcoding**

1006 1. Combine the following components per PCR tube:

Reagent	Volume (μL)
Debranched, cleaned DNA (400 ng)	7.5
Fragmentation Mix (RB01-12)	2.5
Total	10

1007

1008 2. Mix the reagents by flicking the tube and spin briefly.

1009 3. Incubate the samples at 30°C in a thermal cycler for 1 minute and 80°C for 1 minutes with
1010 heated lid off.

1011 4. Spin and pool all the rapid barcoded DNA in 1.5 mL Eppendorf DNA LoBind tube to make
1012 1,200 ng in a volume of 50 μL . Example, for 6 samples, take 200 ng (200 x 6 = 1,200 ng)
1013 DNA per sample.

1014 5. Resuspend the DNA binding beads (e.g., AMPure XP or Aline biosciences) by vortexing.

1015 6. Add 25 μL (0.5x) of resuspended beads to the sample and mix by flicking the tube multiple
1016 times.

1017 7. Incubate the tube for 5 minutes at room temperature.

1018 8. Spin down the sample and pellet on a magnetic rack/plate until the supernatant is clear
1019 and colourless. Keep the tube on the magnet, and carefully pipette off the supernatant.

1020 9. Wash the beads with 250 μl long Fragment Buffer (LFB) without touching/disturbing the
1021 pellet. Remove LFB carefully using a pipette and discard.

1022 Note* Flick the beads to resuspend, spin and put back on magnet and remove supernatant using a pipette. Long
1023 Fragment Buffer Expansion (EXP-LFB001) can be purchased separately from ONT.

1024 10. Repeat the previous LFB washing step.

- 1025 11. Spin down and place the tube back on the magnet. Pipette off any residual supernatant.
1026 Allow to dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1027 12. Remove the tube from the magnetic rack/plate and resuspend the pellet in 22 μ L Elution
1028 Buffer (EB). Spin down briefly and incubate for 2 minutes at room temperature.
- 1029 13. Pellet the beads on a magnetic rack/plate until the eluate is clear and colourless, for at
1030 least 1 minute.
- 1031 14. Remove and retain 20 μ L of eluate containing the DNA library into a clean 1.5 mL
1032 Eppendorf DNA LoBind tube.

1033 **Rapid adapter ligation and loading**

- 1034 15. Quantify 1 μ L rapid barcoded and cleaned DNA using a Qubit fluorometer.
- 1035 16. Add 1 μ L rapid adaptor (RAP) to 10 μ L of barcoded DNA in EB in a PCR tube, flick multiple
1036 times to mix, spin briefly and incubate for 10 minutes at 20°C with the heated lid off.
- 1037 17. Load 100 ng (51.36 fmol; considering 3kb product size) of final prepared library onto a
1038 flow cell following manufacturers recommendation.

1039

1040

1041

1042

1043

1044

1045

1046

1047

1048

1049

1050 **Ligation sequencing (high yield protocol)**

1051 **End prep**

1052 1. Combine the following components per PCR tube:

Reagent	Volume (μL)
Ultra II End-prep reaction buffer	0.875
Ultra II End-prep enzyme mix	0.75
Debranched, cleaned DNA	12
Total	13.625

1053

1054 2. Mix gently by flicking the tube, and spin down.

1055 3. Using a thermal cycler, incubate at 20°C for 5 minutes with heated lid off.

1056 4. Incubate at 65°C for 5 minutes with heated lid on.

1057 **Native barcode ligation and cleanup**

1058 5. Combine the following components per PCR tube:

Reagent	Volume (μL)
Native Barcode	1.25
Blunt/TA Ligase Master Mix	6
End prepped DNA	6
Total	13.25

1059

1060 6. Mix gently by flicking the tube, and spin down.

1061 7. Incubate the reaction for 10 minutes at 20°C with heated lid off.

1062 8. Resuspend the AMPure XP beads by vortexing.

1063 9. Add 13.25 μL of resuspended AMPure XP beads to the reaction and mix by pipetting.

1064 10. Incubate for 5 minutes at room temperature.

1065 11. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the
1066 tube on the magnet, and pipette off the supernatant.

1067 12. Keep the tube on the magnet and wash the beads with 200 μL of freshly prepared 70% ethanol
1068 without disturbing the pellet. Remove the ethanol using a pipette and discard.

- 1069 13. Repeat the previous step.
- 1070 14. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
1071 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1072 15. Remove the tube from the magnetic plate and resuspend pellet in 15 μ L nuclease-free water.
1073 Incubate for 2 min at room temperature.
- 1074 16. Pellet the beads on a magnet until the eluate is clear and colourless.
- 1075 17. Remove and retain 12 μ L of eluate into a clean PCR tube.
- 1076 Measure DNA concentration with Qubit and pool all the barcoded DNA in 1.5 mL Eppendorf DNA
1077 LoBind tube to make 350 ng in a volume of 30 μ L H₂O. Example, for 6 samples, take 58.33 ng (58.33 x
1078 6 = 350 ng) DNA per sample.

1079 **Adapter ligation and cleanup and loading**

- 1080 18. Combine the following components:

Reagent	Volume (μ L)
Pooled barcoded DNA (350 ng)	30
Adapter Mix II (AMII)	5
Ligation Buffer (LNB)	10
Quick T4 DNA Ligase	5
Total	50

- 1081
- 1082 19. Ensure the components are thoroughly mixed by pipetting, and spin down.
- 1083 20. Incubate the reaction for 15 minutes at 20°C.
- 1084 21. Resuspend the AMPure XP beads by vortexing.
- 1085 22. Add 25 μ L (0.5x) of resuspended AMPure XP beads to the reaction and mix by pipetting.
- 1086 23. Incubate for 5 minutes at room temperature.
- 1087 24. Spin down the sample and pellet on a magnet until supernatant is clear and colourless. Keep the
1088 tube on the magnet, and pipette off the supernatant.
- 1089 25. Wash the beads by adding 250 μ L long Fragment Buffer (LFB).
- 1090 Note* Do not flick the beads to resuspend. Just gently wash and remove the supernatant using a
1091 pipette and discard.
- 1092 26. Repeat the previous step.
- 1093 27. Spin down and place the tube back on the magnet. Pipette off any residual supernatant. Allow to
1094 dry for ~30 seconds, but do not dry the pellet to the point of cracking.
- 1095 28. Remove the tube from the magnetic rack and resuspend the pellet in 17 μ L Elution Buffer (EB).
1096 Spin down and incubate for 2 minutes at room temperature.

- 1097 29. Pellet the beads on a magnet until the eluate is clear and colourless, for at least 1 minute.
- 1098 30. Remove and retain 15 μ L of eluate containing the DNA library into a clean 1.5 mL Eppendorf DNA
- 1099 LoBind tube.
- 1100 31. Quantify 1 μ L of adapter ligated and barcoded DNA using a Qubit fluorometer.
- 1101 32. Load 100 ng (51.36 fmol; considering 3kb) of final prepared library onto a flow cell following
- 1102 manufacturers recommendation.
- 1103 Note* The typical library size after this stage is around 3 kb. However, users can verify this by running the library
- 1104 on a gel or TapeStation for a few batches. Once the average expected library size is determined (sample or site-
- 1105 wise), there will be no need to repeat this for every batch of samples.
- 1106 For loading sequencing library or washing flow cells, follow the manufacturers recommended
- 1107 protocols.